Citi: Amgen's (AMGN.US) diversified business growth offsets decline in denosumab product revenue; pipeline execution will determine future prospects.

Zhitong Finance APP has learned that after the U.S. market closed on Tuesday, November 3, Amgen (AMGN.US) announced its third-quarter 2026 results. The financial report shows third-quarter revenue of $10.365 billion, up 8% year over year, beating market expectations of approximately $10.05 billion to $10.07 billion. On profitability, non-GAAP earnings per share were $6.45, up 14% year over year, beating expectations of $5.77 to $5.79; the non-GAAP operating margin was 47.3%, up 0.2 percentage points year over year; free cash flow was $3.7 billion (compared with $4.2 billion in the same period last year).